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Inhibitor of differentiation 1 (ID1) is highly expressed
in glioblastoma stem cells (GSCs). However, the reg-
ulatory mechanism responsible for its role in GSCs is
poorly understood. Here, we report that ID1 activates
GSC proliferation, self-renewal, and tumorigenicity
by suppressing CULLIN3 ubiquitin ligase. ID1 in-
duces cell proliferation through increase of CYCLIN
E, a target molecule of CULLIN3. ID1 overexpression
or CULLIN3 knockdown confers GSC features and
tumorigenicity to murine Ink4a/Arf-deficient astro-
cytes. Proteomics analysis revealed that CULLIN3
interacts with GLI2 and DVL2 and induces their
degradation via ubiquitination. Consistent with ID1
knockdown or CULLIN3 overexpression in human
GSCs, pharmacologically combined control of GLI2
and b-CATENIN effectively diminishes GSC proper-
ties. A ID1-high/CULLIN3-low expression signature
correlates with a poor patient prognosis, supporting
the clinical relevance of this signaling axis. Taken
together, a loss of CULLIN3 represents a common
signaling node for controlling the activity of intra-
cellular WNT and SHH signaling pathways mediated
by ID1.
INTRODUCTION
Glioblastoma (GBM), the most prevalent and malignant primary
brain tumor, has been extensively characterized at themolecular
level, but these findings have not been translated into effective
molecularly targeted therapies (Wen and Kesari, 2008). This fail-
ure may be due to the presence of self-renewing, highly tumori-
genic, stem-like cancer cells commonly referred to as GBMstem
cells (GSCs; Singh et al., 2004). Although the exact identity of
GSCs remains controversial in terms of enrichment markersCell R
This is an open access article undand cell of origin, these cells display therapeutic resistance, inva-
sion into normal brain, angiogenesis, and immune escape (Lathia
et al., 2015; Tanaka et al., 2013; Yi et al., 2011). Like neural stem
cells (NSCs), GSCs are functionally defined through assays of
stem cell marker expression, self-renewal, sustained prolifera-
tion, and differentiation potential. However, GSCs are distin-
guished from NSCs by their chromosomal alterations, cytologic
and nuclear atypia, aberrant differentiation, failure to respond
growth inhibitory cues, and tumor growth. Thus, GSCs may be
differentially regulated from NSCs via alternative molecular tar-
gets. Several studies have shown that GSCs have selective
dependence on molecular targets, including AKT (Bleau et al.,
2009), inducible nitric oxide synthase (Eyler et al., 2011), bone
marrow X-linked kinase (Guryanova et al., 2011), pigment epithe-
lium-derived factor (Yin et al., 2015), GREMLIN1 (Yan et al.,
2014), and LIM-domain only 2 (Kim et al., 2015).
The inhibitor of differentiation (ID) family of proteins critically
regulates normal neural development and gliomagenesis. ID1
leads to anchorage-independent growth of both NSCs and
GSCs through RAP1GAP signaling (Niola et al., 2012, 2013).
We previously suggested that ID3 controls epidermal growth
factor receptor (EGFR) signaling-mediated GSC genesis and
perivascular niche formation through regulation of the angio-
genic cytokines GRO1, interleukin-6 (IL-6), and IL-8 (Jin et al.,
2011), indicating that IDs autonomously support the GSC niche.
Additionally, transforming growth factor b (TGF-b) was shown to
increase GSC self-renewal through SMAD regulation of ID1 and
ID3, which, in turn, control the expression of stem cell factors,
such as LIF, SOX2, and SOX4 (Anido et al., 2010). Platelet-
derived growth factor (PDGF) increased ID4 expression by acti-
vating nitric oxide signaling, and subsequently ID4 induces
expression of JAGGED1, one of NOTCH receptor ligands, by
suppressing miR129 (Jeon et al., 2014). PDGF-ID4-NOTCH
signaling node is activated in GSCs and tumor endothelial cells
in the perivascular microenvironment and accelerates glioma
progression.
Stem cell signaling pathways, such as NOTCH, WNT, and
SHH, are frequently deregulated in a variety of humaneports 16, 1629–1641, August 9, 2016 ª 2016 The Author(s). 1629
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
malignancies and directly induce tumor development and pro-
gression. Thus, targeting these deregulated stem cell signaling
pathways is considered promising therapeutic intervention to
eliminate caner stem cells (Takebe et al., 2011).
NOTCH receptors are expressed in both low-grade and high-
grade gliomas and serve not only as glioma grading and
plausible prognostic factors, but also as therapeutic targets
(Dell’albani et al., 2014). Furthermore, several studies have
demonstrated that NOTCH signaling modulates GSC traits that
are selectively expressed by various transcriptional regulators,
including ID3 (Jin et al., 2011), ID4 (Jeon et al., 2008), interferon
regulatory factor 7 (Jin et al., 2012), and hypoxia inducible factor
1a (Qiang et al., 2012).
In contrast to the widely reported NOTCH signaling activation
in GBMmainly by the classical JAGGED andNOTCH interaction,
the WNT and SHH signaling in GBM is not mediated by their
ligands’ and receptors’ interaction. Instead, WNT and SHH
signaling pathways in these tumors are activated by deregulation
of these signaling pathways related components in respective
signaling pathways: ASCL1 (Rheinbay et al., 2013) and PKM2
(Yang et al., 2011) for WNT/b-CATENIN signaling, and PTCH1
(Munoz et al., 2015) and GLI (Becher et al., 2008) for SHH
signaling. These findings indicate that WNT and SHH signaling
mechanisms in GBM are distinct from those induced in other hu-
man malignancies, and improved understanding of these sig-
naling pathways is urgently needed to provide better control
of GBM.
We now report that ID1 controls GSCs through suppression of
Cullin3 E3 ubiquitin ligase. CULLIN3 suppression simultaneously
activates ligand-independent WNT and SHH signaling by
increasing DVL2 and GLI2 protein levels, respectively. Thus,
CULLIN3 represents a common signaling node controlling the
activity of multiple essential GSC signaling pathways mediated
by ID1.
RESULTS
Ectopic ID1 Expression Confers Tumorigenic Ability to
Primary Mouse Ink4a/Arf/ Astrocyte Cells
To assess tumorigenic potential of ID1, we overexpressed ID1
in non-transformed murine astrocytes with targeted disruption
of p16Ink4a and p19Arf (Ink4a/Arf/ astrocytes), two frequently
inactivated tumor suppressors in human glioblastoma (Cancer
Genome Atlas Research Network, 2008). ID1 overexpression
significantly accelerated cell growth (Figure S1A), including a
‘‘piled up’’ morphology (a typical property of cancer cells)
after confluence (Figure S1B). Furthermore, soft agar analysis
revealed the anchorage-independent growth of Ink4a/Arf/
astrocytes expressing ID1 (Ink4a/Arf/ astrocyte-ID1 cells;
Figure S1C).
ID1 Suppresses the CULLIN3 E3 Ubiquitin Ligase and
Increases CYCLIN E Protein Stability
Because increased cell proliferation is one of the obvious
phenotypic changes in Ink4a/Arf/ astrocyte-ID1 cells, we
examined expression levels of CYCLINs in these cells.
Immunoblot analysis showed that CYCLIN E, CYCLIN D, and
CYCLIN A proteins increased in Ink4a/Arf/ astrocyte-ID11630 Cell Reports 16, 1629–1641, August 9, 2016cells compared to control Ink4a/Arf/ astrocytes (Figure 1A).
The change in CYCLIN D and CYCLIN A proteins by ID1 over-
expression was correlated with an increase in mRNA levels.
However, Cyclin E mRNA levels did not increase in response
to ID1 overexpression (Figure 1B). In lieu of this, we examined
the protein half-life of CYCLIN E in Ink4a/Arf/ astrocyte-ID1
cells using a translation inhibitor (cycloheximide [CHX]) and
found that ID1 overexpression markedly increased CYCLIN E
protein stability (Figures 1C and S1D).
Because CYCLIN E protein stability is primarily regulated by
ubiquitination (Singer et al., 1999), we examined expression
levels of several ubiquitin ligases in Ink4a/Arf/ astrocyte-ID1
cells and found that CULLIN3 wasmarkedly decreased following
ID1 overexpression (Figure 1D), indicating that CULLIN3 may be
a key downstream target of ID1. We found that there are six
E-box elements (binding sites of bHLH transcription factors)
located in the Cullin3 promoter (up to 1267 bp upstream of
the transcriptional start site). A luciferase reporter assay using
a Cullin3-promoter construct revealed that ID1 significantly
repressedCullin3 promoter activity in a dose-dependent manner
(Figure 1E), indicating that ID1 mediates transcriptional suppres-
sion of Cullin3. Moreover, CYCLIN E expression increased
following CULLIN3 knockdown in Ink4a/Arf/ astrocytes (Fig-
ure 1F) and decreased upon CULLIN3 overexpression in Ink4a/
Arf/ astrocyte-ID1 cells (Figure 1G). Fluorescence-activated
cell sorting (FACS) analysis revealed that ID1 overexpression
and CULLIN3 knockdown in the Ink4a/Arf/ astrocytes in-
creased the S phase cell population with markedly reduction in
the G0/G1 and G2/M phase populations. However, CULLIN3
overexpression in Ink4a/Arf/ astrocyte-ID1 cells led to dra-
matic increase inG0/G1 andG2/Mphase populations (Figure 1H).
Taken together, these results indicate that the ID1-CULLIN3 reg-
ulatory axis plays a crucial role in the Ink4a/Arf/ astrocyte
proliferation.
ID1-Mediated Suppression of CULLIN3 Confers GSC
Features and a Malignant Glioblastoma-Forming Ability
to Ink4a/Arf/ Astrocytes
Of interest, ID1 overexpression in Ink4a/Arf/ astrocytes also
led to reduced expression of the differentiated astrocyte marker,
GFAP, and increased expression of the neural stem cell marker,
NESTIN (Figure S1E). Thus, we speculated that ID1-mediated
suppression of CULLIN3 may render Ink4a/Arf/ astrocytes
less differentiated. To elucidate role of ID1 in GSCs genesis,
we examined sphere forming ability (a surrogate marker
of GSCs self-renewal), stem cell marker expression, and
tumorigenicity.
We found that ID1 overexpression or CULLIN3 knockdown
in Ink4a/Arf/ astrocytes increased sphere formation,
whereas restoration of CULLIN3 in Ink4a/Arf/ astrocyte-ID1
cells significantly decreased sphere formation (Figures 2A,
2B, S2A, and S2B). However, CYCLIN E overexpression alone
did not impart sphere-forming ability to Ink4a/Arf/ astrocytes,
and that CYCLIN E knockdown failed to inhibit the sphere for-
mation of Ink4a/Arf/ astrocyte-ID1 cells (Figures 2A, 2B, and
S2C). FACS analysis revealed that stem cell markers NESTIN-
and SOX2-positive cells were markedly enriched in Ink4a/
Arf/ astrocyte-ID1 and Ink4a/Arf/ astrocyte-shCULLIN3
Figure 1. ID1 Transcriptionally Represses
Expression of the E3 Ubiquitin Ligase,
Cullin3
(A) CYCLIN A, D, and E protein levels in Ink4a/
Arf/ astrocyte-ID1 and control Ink4a/Arf/
astrocytes (VEC).
(B) Cyclin A, D, and EmRNA levels in Ink4a/Arf/
astrocyte-ID1 and control Ink4a/Arf/ astrocytes
(VEC). *p < 0.05; **p < 0.01 (n = 3). Data are
mean ± SD.
(C) CYCLIN E protein degradation in Ink4a/Arf/
astrocyte-ID1 and control Ink4a/Arf/ astrocytes
(VEC) following exposure to cycloheximide (CHX,
50 mM) for the indicated times.
(D) The mRNA expression levels of several E3
ubiquitin ligases in Ink4a/Arf/ astrocyte-ID1 and
control Ink4a/Arf/ astrocytes (VEC). A right
graph shows quantitative level of Cullin3 mRNA in
these cells. *p < 0.05 (n = 3). Data are mean ± SD.
(E) Cullin3-promoter luciferase reporter activity in
the presence (0.25–1 mg) or absence of ID1. *p <
0.05 (n = 3). Data are mean ± SD.
(F) CULLIN3 and CYCLIN E protein levels in Ink4a/
Arf/ astrocytes and Ink4a/Arf/ astrocyte-
shCULLIN3 cells.
(G) CULLIN3 and CYCLIN E protein levels in Ink4a/
Arf/ astrocyte-ID1 and Ink4a/Arf/ astrocyte-
ID1-CULLIN3 cells.
(H) Cell cycle of Ink4a/Arf/ astrocytes, Ink4a/
Arf/ astrocyte-ID1, Ink4a/Arf/ astrocyte-
shCULLIN3, and Ink4a/Arf/ astrocyte-ID1-
CULLIN3 cells was analyzed by FACS.cells, but not in Ink4a/Arf/ astrocyte-VEC and Ink4a/Arf/
astrocyte-CYCLIN E cells (Figure 2C). Conversely, differenti-
ated astrocyte cell marker S100b-positive cells, which are a
major subpopulation in Ink4a/Arf/ astrocyte-VEC and Ink4a/
Arf/ astrocyte-CYCLIN E cells, dramatically decreased in
Ink4a/Arf/ astrocyte-ID1 and Ink4a/Arf/ astrocyte-shCUL-
LIN3 cells (Figure 2C). Next, we compared the brain tumor-
initiating ability of Ink4a/Arf/ astrocyte-ID1, Ink4a/Arf/
astrocyte-CYCLIN E, Ink4a/Arf/ astrocyte-shCULLIN3, and
Ink4a/Arf/ astrocyte-VEC cells using orthotopic injection
model. Ink4a/Arf/ astrocyte-ID1 and Ink4a/Arf/ astrocyte-
shCULLIN3 cells, but not Ink4a/Arf/ astrocyte-CYCLIN E
and Ink4a/Arf/ astrocyte-VEC cells, gave rise to brain tumors
(Figure 2D) displaying histological features associated with
high-grade glioma, such as focal necrosis, high invasiveness,
massive hemorrhage, and pleomorphic nuclei of tumor cells
(Figure 2E). Taken together, these in vitro and in vivo results
suggest that ID1-mediated suppression of CULLIN3 confers
stem cell-like features and tumorigenicity to Ink4a/Arf/
astrocytes.Cell ReID1-CULLIN3 Axis Controls CYCLIN
E, DVL2, and GLI2 Protein
Polyubiquitination
Because CULLIN3 is an E3 ubiquitin
ligase, interaction of CULLIN3 with
proteins is an important event to regu-
late protein degradation. To understandthe molecular mechanisms underlying the acquisition of
GSCs feature and tumorigenicity in Ink4a/Arf/ astrocytes
by the ID1-CULLIN3 regulatory axis, we employed immuno-
precipitation of Flag-CULLIN3 in HEK293T cells followed by
MALDI-TOF mass spectroscopy (MALDI-TOF MS) to identify
CULLIN3-interacting proteins. The method was validated by
identifying four CYCLIN E peptides that interact with CULLIN3
(Figure 3A). Of interest, we identified GLI2 and DVL2 as
CULLIN3-interacting proteins, which are involved in the SHH
and WNT signaling pathways, respectively (Figures 3A and
3B), and therefore would link the ID1-CULLIN3 axis with
stem cell signaling. The interactions of CULLIN3 with CYCLIN
E, GLI2, and DVL2 were further confirmed by immunoprecipi-
tation of Flag-CYCLIN E and Myc-CULLIN3 (Figure 3C), Myc-
GLI2 and Flag-CULLIN3 (Figure 3D), and Flag-DVL2 and Myc-
CULLIN3 (Figure 3E), respectively. Poly-ubiquitinated CYCLIN
E, GLI2, and DVL2 levels were reduced by ID1 overexpression
but were recovered by co-expression of CULLIN3 with ID1
(Figures 3F–3H). The luciferase reporter assays revealed
that SHH (Gli-BS-luciferase) and WNT/b-catenin signalingports 16, 1629–1641, August 9, 2016 1631
Figure 2. The ID1-CULLIN3 Regulatory Axis Stimulates GSC Genesis and Malignant Glioma Formation
(A) Representative photos showing tumorspheres generated from Ink4a/Arf/ astrocytes expressing empty vector (VEC; shNT+Puro), ID1, shCULLIN3, CYCLIN
E, ID1+shCYCLIN E, and ID1+CULLIN3. Scale bar, 20 mm.
(B) Tumorsphere formation ability of Ink4a/Arf/ astrocytes expressing empty vector (VEC), CYCLIN E, shCULLIN3, ID1, ID1+shCYCLIN E, and ID1+CULLIN3.
**p < 0.01 (n = 3). Data are mean ± SD.
(C) FACS shows NESTIN+, SOX2+, and S100b+ cell proportions in the Ink4a/Arf/ astrocyte-VEC, Ink4a/Arf/ astrocyte-ID1, Ink4a/Arf/ astrocyte-shCUL-
LIN3, and Ink4a/Arf/ astrocyte-CYCLIN E. **p < 0.01 (n = 3). Data are mean ± SD.
(D) The tumor-forming frequency of Ink4a/Arf/ astrocyte-VEC, Ink4a/Arf/ astrocyte-ID1, Ink4a/Arf/ astrocyte-shCULLIN3, and Ink4a/Arf/ astrocyte-
CYCLIN E post-orthotopic implantation (upper table). Representative H&E staining of mice whole brains implanted with Ink4a/Arf/ astrocyte-shCULLIN3, and
Ink4a/Arf/ astrocyte-CYCLIN E (lower images). Scale bar, 2 mm.
(E) Representative images of H&E staining showing histopathological features of brain tumors. Scale bar, 250 mm.
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Figure 3. ID1 Inhibits CYCLIN E, GLI2, and
DVL2 Protein Degradation through CULLIN3
Repression
(A) Immunoprecipitation was performed using anti-
Flag M2 affinity resin and extracts of HEK293T
cells transfected with Flag-CULLIN3. The immu-
noprecipitated protein complex was visualized by
silver staining and identified by MALDI-TOF MS
analysis. The identified peptide sequences of
GLI2, DVL2, and CYCLIN E are shown in the right
panel.
(B) Interactions of CULLIN3 with GLI2, DVL2, and
CYCLIN E were confirmed using immunoprecipi-
tation-western blot analyses in HEK293T cells.
(C–E) Interactions of CULLIN3 with CYCLIN E (C),
GLI2 (D), and DVL2 (E) were confirmed by ectopic
expression of Myc- or Flag-tagging exogenous
genes in HEK293T cells.
(F–H) Polyubiquitination of CYCLIN E (F), GLI2 (G),
and DVL2 (H) by the ID1-CULLIN3 regulatory axis
in HEK293T cells.
(I) HEK293T cells were co-transfected with pGL3-
Gli-BS (containing Gli-binding sites) and ID1 or
CULLIN3, plus the corresponding control vector.
**p < 0.01 (n = 3). Data are mean ± SD.
(J) HEK293T cells were co-transfected with pTOP-
FLASH (containing TCF/LEF-binding sites) and ID1
or CULLIN3, plus the corresponding control vec-
tor. **p < 0.01 (n = 3). Data are mean ± SD.(pTOP-luciferase) activities were increased by ID1 overexpres-
sion and were markedly reduced by CULLIN3 overexpression
(Figures 3I and 3J). Taken together, these results indicate
that ID1-mediated suppression of CULLIN3 may activate
SHH and WNT signaling by stabilizing GLI2 and DVL2 pro-
teins, respectively.Cell ReID1-CULLIN3 Regulatory Axis
Activates Intracellular WNT and
SHH Signaling in Ink4a/Arf/
Astrocytes
To confirm the functional significance of
the biochemical findings from our glio-
blastoma models, we performed immu-
noprecipitations with CULLIN3-specific
antibodies in Ink4a/Arf/ astrocyte-ID1
and Ink4a/Arf/ astrocyte-VEC cells.
ID1 overexpression markedly reduced
the interactions of CULLIN3 with either
DVL2 or GLI2 through suppression of
CULLIN3 expression (Figure 4A). To iden-
tify poly-ubiquitinated GLI2 and DVL2
levels, we performed immunoprecipita-
tions and denature immunoprecipitations
with GLI2- and DVL2-specific antibodies.
Poly-ubiquitinated GLI2 and DVL2 levels
were reduced by CULLIN3 knockdown
in Ink4a/Arf/ astrocytes (Figures 4B
and S2D). Furthermore, we examined
the protein half-life of DVL2 and GLI2 in
Ink4a/Arf/ astrocyte-VEC, Ink4a/Arf/astrocyte-ID1, and Ink4a/Arf/ astrocyte-ID1+CULLIN3 cells
by CHX treatment. ID1 overexpression markedly increased
DVL2 and GLI2 protein stability relative to VEC and ID1+CUL-
LIN3-overexpressing cells (Figures S2E and S2F). However,
qRT-PCR analysis revealed that Dvl2 and Gli2 mRNA
levels were not significantly changed by ID1 overexpressionports 16, 1629–1641, August 9, 2016 1633
Figure 4. ID1-CULLIN3 Axis Activates WNT
and SHH Pathways in Ink4a/Arf/ Astro-
cytes
(A) Interactions of endogenous CULLIN3 with GLI2
or DVL2 in Ink4a/Arf/ astrocyte-ID1 and control
Ink4a/Arf/ astrocytes.
(B) Polyubiquitination of GLI2 and DVL2 in Ink4a/
Arf/ astrocyte-shCULLIN3 and control Ink4a/
Arf/ astrocytes.
(C) SHH (GLI1 and GLI2) and WNT (P-GSK3a/b,
b-CATENIN and c-MYC) signaling protein levels in
Ink4a/Arf/ astrocytes, Ink4a/Arf/ astrocyte-
ID1, and Ink4a/Arf/ astrocyte-ID1-CULLIN3.
(D) Expression levels of Gli1 and c-Myc mRNAs in
Ink4a/Arf/ astrocytes, Ink4a/Arf/ astrocyte-
ID1, and Ink4a/Arf/ astrocyte-ID1-CULLIN3.
**p < 0.01 (n = 3). Data are mean ± SD.(Figure S2G). These results indicate that ID1 regulates DVL2 and
GLI2 expression at a post-transcriptional level by suppressing
CULLIN3 expression. Simultaneous activation of SHH and
WNT signaling by the ID1-CULLIN3 regulatory axis was con-
firmed by the protein levels of GLI2, GLI1 (increased by SHH
signaling; Ruiz i Altaba, 1998), DVL2, p-GSK3a/b, b-CATENIN,
and c-MYC (a target gene of WNT/b-CATENIN signaling)
in Ink4a/Arf/ astrocyte-VEC, Ink4a/Arf/ astrocyte-ID1,
and Ink4a/Arf/ astrocyte-ID1+CULLIN3 cells (Figure 4C).
The increased Gli1 and c-Myc mRNA levels observed in Ink4a/
Arf/ astrocyte-ID1 cells were dramatically reduced by
CULLIN3 restoration (Ink4a/Arf/ astrocyte-ID1+CULLIN3
cells; Figure 4D). These results suggest the ID1-CULLIN3 axis
acts as a ligand-independent upstream regulator of SHH/WNT
signaling.
ID1 Regulates Cancer Stem Cell Properties and SHH/
WNT Signaling in Primary Human GSCs
To elucidate the biological effects of ID1-CULLIN3 axis in
GSCs, we first found that ID1 expression was significantly
increased in various GSCs derived from patients with glioblas-
toma (Figure S3A), and CULLIN3 expression was significantly
decreased in several GSCs (Figure S3B). An inverse correlation
was observed between ID1 and CULLIN3 expression in GSCs
(Figure S3C). Then, we generated two ID1 knockdown (KD)1634 Cell Reports 16, 1629–1641, August 9, 2016GSC cultures; GSC8 (expressing high
levels of ID1) and GSC2 (expressing mod-
erate levels of ID1) using two non-overlap-
ping ID1-30 UTR targeting short hairpin
RNAs (shRNAs), and along with a non-tar-
geting shRNA sequence (shNT) to rule out
off-target effects. In vitro limiting dilution
assay revealed that ID1 depletion using
ID1 30-UTR-targeted shRNAs significantly
reduced tumorsphere-forming ability of
GSC8 cells, and that re-overexpression
of ID1-coding DNA sequence (CDS)
rescued tumorsphere-forming ability in
ID1-depleted GSCs (Figures 5A and
S3D). A previous study has demonstrated
that ID1 and ID3 have a possible overlapping function in mouse
embryo development (Lyden et al., 1999). Therefore, we exam-
ined the role of ID3 in tumorsphere-forming ability of ID1-
depleted GSCs. Ectopic ID3 expression did not significantly
rescue tumorsphere-forming ability in ID1-depleted GSCs (Fig-
ures S3E and S3F), supporting a non-overlapping role of IDs in
GSCs. FACS analysis revealed that ID1 depletion in GSC8 and
GSC2 reduced GSC markers NESTIN- and SOX2-positive cells,
while increased cells expressing differentiation markers, such as
S100b (an astrocyte marker), TUJ1 (neuronal cell marker), and
O4 (oligodendrocyte marker) (Figures 5B and S4A), indicating
ID1 as a differentiation inhibitor. To assess the tumorigenic role
of ID1 in GSCs, we orthotopically implanted 1,000 control shRNA
or ID1-KD GSCs into nude mice. After 40 days, neurological
signs and brain tumors were observed in mice implanted with
control shRNA GSC8 cells, but not in mice implanted with ID1-
KD GSC8 cells (Figure 5C). We also assessed tumorigenic po-
tential of ID1 by overexpressing ID1 in GSC5 cells that express
endogenous ID1 similar to normal astrocyte cells (Figure S3A).
The orthotopic injection of GSCs into nude mice showed that
ID1-overexpressing GSC5 displayed faster tumor growth than
control cells (Figure S5A).
We also confirmed that ID1 depletion in GSC8 cells increased
the interactions of CULLIN3 with both DVL2 and GLI2, possibly
due to increased CULLIN3 (Figure 5D). ID1 depletion in GSC8
Figure 5. The Role of ID1 in the Mainte-
nance of Human GSC Properties
(A) In vitro limiting dilution assays with different
plating densities were used to determine the tu-
morsphere formation ability in GSC8 cells trans-
duced with shNT, shID1-1 (30 UTR targeted), and
shID1-2 (30 UTR targeted), and in ID1-CDS-over-
expressing GSC8 cells transduced with shNT,
shID1-1, and shID1-2. **p < 0.01 (n = 24).
(B) FACS showed cell proportions of NESTIN+,
SOX2+, S100b+, TUJ1+, and O4+ cells in ID1
knockdown and control GSC8. **p < 0.01 (n = 3).
Data are mean ± SD.
(C) Tumor-forming frequency of ID1 knockdown
and control GSCs 40 days post-orthotopic im-
plantation (upper table). Representative H&E
staining of mice whole brains implanted with ID1
knockdown and control GSCs (lower images).
(D) Interactions of endogenous CULLIN3with GLI2
or DVL2 in GSC8 cells transduced with shNT and
shID1.
(E) SHH and WNT signaling protein levels in GSC8
cells transduced with shNT, shID1-1, and shID1-2.
(F) Gene set enriched by WNT and SHH signaling
was analyzed by GSEA in GSC8 transduced with
shNT and shID1. NES, normalized enrichment
score; FDR, false discovery rate q value.and GSC2 cells reduced the downstream SHH and WNT sig-
naling protein expression and ID1 overexpression in GSC5 cells
increased the downstream SHH and WNT signaling protein
expression (Figures 5E, S4B, and S5B). The qRT-PCR analysis
revealed that ID1 did not significantly change DVL2 and GLI2
mRNA levels in GSC8 (Figure S5D), GSC2 (Figure S4C), and
GSC5 cells (Figure S5C). Next, we conducted a gene set enrich-
ment analysis (GSEA) of the downstream-response genes
known to be regulated by SHH and WNT signaling pathways us-
ing microarray data of a control and ID1-KDGSCs. ID1 depletion
in GSCs markedly repressed expression of genes enriched by
SHH and WNT signaling pathways (Figures 5F and S4D). Taken
together, these results indicate that ID1 is a key GSC regulator
and activates SHH and WNT signaling pathways.
CULLIN3 Suppresses Cancer Stem Cell Properties and
SHH/WNT Signaling in Primary Human GSCs
Next, we examined biological effects of CULLIN3 in GSC cells.
CULLIN3 overexpression in GSC8 cells inhibited SHH andCell ReWNT signaling protein expression (Fig-
ure 6A). The luciferase reporter assays re-
vealed that SHH and WNT/b-CATENIN
signaling activities were decreased by
CULLIN3 overexpression (Figure 6B).
We also found that CULLIN3 overexpres-
sion led to marked decreases in expres-
sion of genes that are downstream of
SHH (GLI1) and WNT (c-MYC) signaling
pathways (Figure 6C). FACS analysis
showed that CULLIN3 overexpression in
GSC8 reduced stem cell marker-positive
cells (NESTIN and SOX2), while increased
cells expressing differentiation markers (S100b, TUJ1, and O4;
Figure 6D). In vitro limiting dilution assay revealed that CULLIN3
overexpression significantly reduced tumorsphere-forming abil-
ity of GSC8 cells (Figure 6E). To elucidate the tumorigenic role of
CULLIN3 in GSCs, we orthotopically implanted 1,000 control or
CULLIN3-overexpressing GSCs into nude mice. After 40 days,
neurological signs and brain tumors were observed in mice
implanted with control GSC8 cells, but not in mice implanted
with CULLIN3-overexpressing GSC8 cells (Figure 6F). Taken
together, these results indicate that CULLIN3 is a key suppressor
for GSCs and inhibits SHH and WNT signaling pathways.
Clinical Relevance of an ID1-CULLIN3 Expression
Signature
To assess the clinical relevance of ID1 and CULLIN3, we first
analyzed ID1 and CULLIN3 expression in various tumor types,
WHO grades, GBM DNAmethylation status, and GBM subtypes
in the National Cancer Institute’s Repository for Molecular
Brain Neoplasia Data (REMBRANDT; Madhavan et al., 2009;ports 16, 1629–1641, August 9, 2016 1635
Figure 6. The Role of CULLIN3 in the Main-
tenance of Human GSC Properties
(A) SHH andWNT signaling protein levels in control
GSC8 (VEC) and GSC8-CULLIN3 cells.
(B) Control GSC8 (VEC) and GSC8-CULLIN3 cells
were transfected with pGL3-Gli-BS (containing
Gli-binding sites) or pTOP-FLASH (containing
TCF/LEF-binding sites) vectors. **p < 0.01 (n = 3).
Data are mean ± SD.
(C) SHH and WNT signaling-downstream genes in
control GSC8 and GSC8-CULLIN3 cells. Data are
mean ± SD.
(D) FACS showed cell proportions of NESTIN+,
SOX2+, S100b+, TUJ1+, and O4+ cells in control
GSC8 and GSC8-CULLIN3 cells. **p < 0.01 (n = 3).
Data are mean ± SD.
(E) In vitro limiting dilution assays with different
plating densities were used to determine the tu-
morsphere formation ability in control GSC8 and
GSC8-CULLIN3 cells. **p < 0.01 (n = 24).
(F) Tumor-forming frequency of control GSC8
and GSC8-CULLIN3 cells 40 days post-orthotopic
implantation (upper table). Representative H&E
staining of mice whole brains implanted with con-
trol GSC8 and GSC8-CULLIN3 (lower images).Figure S6A). As shown in Figure 7A, ID1 expression levels were
significantly increased in all classifications of gliomas including
astrocytoma, oligodendroglioma, WHO grade II and III gliomas,
and grade IV GBMs compared to non-malignant brain tissues
(Figures S6B and S6F), whereas CULLIN3 expression was sig-
nificantly reduced in all gliomas (Figures S6C and S6G). Interest-
ingly, ID1 and CULLIN3 expression remained significantly
anticorrelated in the WHO grade IV GBM patient group, the rela-
tionship was not significant in lower-grade glioma groups such
as astrocytoma, oligodendroglioma, and WHO grade II and III
gliomas themselves, indicating that ID1-CULLIN3 signaling
pathway might be more activated in GSC-enriched high-grade
gliomas, GBMs (Figures 7B, S6D, and S6E). Furthermore,
CULLIN3 high expression groups including ID1hi/CUL3hi and
ID1lo/CUL3hi in all gliomas significantly extended patient
survival compared to ID1hi/CUL3lo and ID1lo/CUL3lo groups (Fig-
ures S6H and S6I). In GBM, ID1 expression was significantly
increased in classical subtype samples compared to neural sub-
type tumors (Figures 7A and S6J), but CULLIN3 expression was
significantly decreased in classical and mesenchymal subtypes
compared to proneural and neural subtypes (Figures 7A and
S6K). ID1 and CULLIN3 expression exhibited a strong negative
correlation in proneural subtype samples (Figures 7B and S6L).
Furthermore, grouping patients according to ID1 and CULLIN31636 Cell Reports 16, 1629–1641, August 9, 2016expression in GBM displayed that the
ID1lo/Cul3hi patient group comprising
44% neural, 30% proneural, 21% clas-
sical, and 5% mesenchymal GBM sub-
types was significantly independent from
ID1hi/CUL3lo and ID1lo/CUL3lo groups,
whichwere composed of high percentage
of classical and mesenchymal subtypes
(Figure 7C). Indeed, the ID1hi/CUL3logroup exhibited a significantly poorer patient survival compared
to the ID1lo/CUL3hi group (Figures 7D and S6M). To further eval-
uate the clinical significance of the ID1-CULLIN3 signature, we
performed multivariate analyses considering age, radiotherapy,
chemotherapy, surgery, and ID1/CULLIN3 expression levels in
186 glioblastoma specimens (full information for patients is pro-
vided in the REMBRANDT database). As shown in Table S1, ID1/
CULLIN3 expression levels and age can be used as two inde-
pendent prognostic markers for GBM patient survival. Thus,
the prognostic significance of the ID1:CULLIN3 ratio supports
the clinical relevance of this signaling axis.
To assess whether the ID1 and CULLIN3 expression corre-
lates with SHH and WNT signaling activation in glioma patient
samples, we analyzed the correlation between ID1 or CULLIN3
expression and HH orWNT signature (analyzed by single sample
GSEA with SHH and WNT gene set in Figures 5F and S4D), li-
gands, and receptors (Figure 7E). SHH and WNT signatures
showed significant positive and negative correlations with ID1
and CULLIN3 expression, respectively, but ligands and recep-
tors did not exhibit correlation with ID1 andCULLIN3 expression,
indicating that the ID1-CULLIN3 axis might regulate SHH and
WNT signaling in ligand-independent manner. Conversely,
desert hedgehog (DHH), WNT11, and WNT8A showed signifi-
cant negative correlation with ID1 and CULLIN3 expression,
indicating that theseHH andWNT ligandsmay contribute to poor
overall survival of the ID1lo/CUL3lo glioma patient group (Figures
S6H and S6I).
Pharmacological Blockade of Intracellular SHH/WNT
Signaling and a Ligand-Independent Activation of SHH/
WNT Signaling by ID1-CULLIN3 Axis
To directly evaluate whether the ID1-CULLIN3 axis acts as a
ligand-independent SHH/WNT signaling regulator, we first in-
hibited WNT and SHH receptor signaling molecules, LRP5/6
and Smoothened, by treatment with siLRP5/6 (Figure S7A) and
cyclopamine, respectively, in GSC5-VEC and GSC5-ID1 cells.
Then, these cells were transfected with pTOP-FLASH-luciferase
and Gli-BS-luciferase vectors. After treatment of WNT and SHH
ligands (WNT3a and SHH-N), WNT and SHH signaling activities
were examined by analyzing luciferase activity. The pTOP and
Gli-BS luciferase activities in GSC5-VEC cells induced by
WNT3a and SHH-N treatment were significantly decreased
upon siLRP5/6 and cyclopamine treatment (Figures 7F and
7G). However, compared to GSC5-VEC cells, GSC5-ID1 cells
treated with WNT3a and SHH-N or siLRP5/6 and cyclopamine
did not exhibit any change in the markedly increased pTOP
and Gli-BS luciferase activities (Figures 7F and 7G). These re-
sults indicate that ID1 regulates a ligand-independent activation
of WNT and SHH signaling pathways. Next, we examined tumor-
sphere-forming ability of Ink4a/Arf/ astrocyte-ID1 and GSC8
cells by treating them with JW67 (intracellular WNT signaling in-
hibitor), GANT61 (intracellular SHH signaling inhibitor), and
combinatorial treatments (JW67+GANT61). Although single
treatments of JW67 and GANT61 significantly reduced tumor-
sphere forming ability of Ink4a/Arf/ astrocyte-ID1 and GSC8
cells compared to DMSO treatment, combinatorial treatment
showed most significant suppression of tumorsphere forming
ability (Figures 7H, 7I, S7B, and S7C). To assess biological roles
of SHH andWNT signaling onGSCs’ genesis, we overexpressed
b-CATENIN S37A (a constitutively active form) andGLI2 in Ink4a/
Arf/ astrocyte-CYCLIN E cells that do not display GSCs’ fea-
tures (Figures 2 and S7D, inset). The b-CATENIN S37A and
GLI2 markedly induced in vitro tumorsphere formation (Fig-
ure S7D) and in vivo subcutaneous tumor formation (Figure S7E).
However, overexpression of b-CATENIN S37A and GLI2 in con-
trol Ink4a/Arf/ astrocyte cells did not give rise to tumors at the
same experimental conditions (data not shown). These results
indicate that simultaneous induction of SHH and WNT signaling
pathways by ID1-CULLIN3 regulatory axis plays a crucial role in
maintaining GSC properties, suggesting that the combined inhi-
bition of multiple stem cell signaling pathways should be an
effective treatment strategy for GSC-enriched glioblastoma.
Overall, our results suggest that ID1-mediated CULLIN3 sup-
pression leads to a cell-autonomous acquisition of cancer
stem cell signaling by direct activation of cell proliferation and
ligand-independent WNT/SHH signaling through CYCLIN E,
GLI2, and DVL2 protein stabilization.
DISCUSSION
Current molecularly targeted therapeutics against cancer stem
cells exploits the core regulation of embryonic and tissue-spe-cific stem cells. NOTCH, WNT, HEDGEHOG, and PI3K are
some pathways that promote stem cell self-renewal. Inhibitors
of these pathways often enter clinical trials with early promising
results, even against glioblastoma; however, they eventually
culminate in failure (Wen and Kesari, 2008; Takebe et al.,
2011). Thus, paradigms focusing on signaling nodes, which
control multiple elements of stem cell signaling, may be benefi-
cial. In this study, we demonstrate that ID1 regulates SHH/
WNT signaling through suppressing CULLIN3-mediated GLI2
and DVL2 protein degradation and suggest that ID1-CULLIN3
is an important signaling node inmultiple core stem cell signaling
pathways, converging on a single restriction point and demon-
strating direct clinical implications.
Proteasome proteolysis is an intracellular autonomous mech-
anism to control essential cellular functions, including cell-cycle
regulation and signal transduction. Inactivation of proteasome
proteolysis stabilizes several proto-oncogenic and stem cell fac-
tors, including many IDs (Williams et al., 2011), TGF-b receptor I
(Eichhorn et al., 2012), and REST (Huang et al., 2011). Further-
more, although GLI1 and DVL2 expression levels are both upre-
gulated in malignant gliomas (Clement et al., 2007; Pulvirenti
et al., 2011), activation of SHH/WNT signaling components by
genetic mutations have not yet been reported. Our studies
demonstrated that CULLIN3 interacts with and degrades SHH/
WNT intracellular signaling transmitters, such as GLI2 and
DVL2, by poly-unbiquitination-mediated proteolysis, indicating
that the ID1-CULLIN3 axis activates SHH/WNT signaling path-
ways in an environmentally independentmanner. In this signaling
cascade, ID1 and CULLIN3 are the master switches for multi-
intracellular signaling pathways.
Our findings show that GSCs could be generated and main-
tained by simultaneous control of multiple ligand/receptor-
independent, intracellular stem cell signaling networks activated
by deregulated proteolysis. Thus, directional manipulation of
multi-signaling network nodes, such as the ID1-CULLIN3
signaling axis, should be applicable to the development of a
treatment strategy that targets GSCs for the effective eradication
of glioblastoma.EXPERIMENTAL PROCEDURES
Cell Cultures
Normal human astrocytes (NHAs; Cambrex Bio Science) were maintained
in astrocyte growth medium from an AGM-Astrocyte Medium Bullet Kit
(Cambrex Bio Science). Murine Ink4a/Arf/ astrocytes were isolated from
the cerebral cortices of 5-day-old Ink4a/Arf/ knockout mice and were main-
tained in DMEM enriched with 10% fetal bovine serum (FBS; HyClone).
GSC1(X01), GSC2(X02), and GSC3(X03) were obtained from Dr. A. Soeda
(Soeda et al., 2009); GSC4 (436), GSC5 (448), GSC6 (559T), and GSC8 were
obtained from Dr. D. Nam (Joo et al., 2008); GSC7 (Aju14) was obtained
from Dr. S. Kim (Jeon et al., 2014); and IN83 and IN1123 were obtained from
Dr. I. Nakano (Jijiwa et al., 2011). All tested GSCs were cultured using neuro-
basal medium (Invitrogen) supplemented with modified N2, B27, epidermal
growth factor (EGF, 20 ng/ml; R&D Systems), and basic fibroblast growth fac-
tor (bFGF, 20 ng/ml; R&D Systems). Cell growth and tumorsphere formation
assays were performed as described previously (Jeon et al., 2008). The tumor-
sphere forming ability of in vitro limiting dilution assayswas evaluated using the
extreme limiting dilution analysis function (http://bioinf.wehi.edu.au/software/
elda/). Cells were treated with GANT61 (Gli antagonist; 5.5 and 10 mM; Tocris
Bioscience; Lauth et al., 2007) and JW67 (b-catenin inhibitor; 4.1 and 16.1 mM;Cell Reports 16, 1629–1641, August 9, 2016 1637
Figure 7. The ID1-CULLIN3 Expression Profile Acts as a Prognostic Indicator for Brain Tumor Patients
(A) Heatmap showing ID1, CULLIN3 expression, and patient survival time in tumor types, WHO grades, GBM DNA methylation status, GBM subtypes in
REMBRANDT database.
(B) Dot plot showing correlation coefficients (r values) of ID1 and CULLIN3 expression in tumor types, WHO grades, GBMDNAmethylation status, GBM subtypes
in REMBRANDT database.
(legend continued on next page)
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Tocris Bioscience; Waaler et al., 2011) for 2 weeks to monitor limiting dilution
assays. Cells were treated with siNT (50 nM; Sigma; SIC001), siLRP5/6 (used
for WNT receptor inactivation; 50 nM; Sigma; Hs01-00086820/Hs01-
00039493), cyclopamine (Smoothened inhibitor; 10 mM; Sigma), human sonic
hedgehog (Shh-N; 1 mg/ml; R&D Systems), and human WNT3a (100 ng/ml;
R&D Systems).
Immunoblot Assays
Protein (30–100 mg) was resolved by 10% SDS-PAGE (NuPAGE Bis-Tris
gel, Invitrogen) and transferred to polyvinylidene fluoride (PVDF) mem-
branes (Millipore). The membranes were blocked with 5% non-fat milk
and incubated with specific antibodies against target proteins (antibodies
used are listed in Table S4). Cells were treated with cycloheximide (CHX,
50 mM; Cell Signaling Technology) to detect CYCLIN E, DVL2, and GLI2
protein stability.
Orthotopic Implantation Assay
Cells (102 and 104) were stereotactically injected into the left striata of nude
mice (BALB/c nu/nu mice) for orthotopic implantation (coordinates: anterior-
posterior, +2; medial-lateral, +2; dorsal-ventral, –3 mm from the bregma). All
mouse experiments were approved by the animal care committee of Korea
University and were performed in accordance with government and institu-
tional guidelines and regulations.
Microarray and Gene Set Enrichment Analysis
Gene expression profiling was performed using HumanRef-8 v3 Expression
BeadChips (Illumina) with 24,526 transcript probes. The samples were pre-
pared according to the manufacturer’s recommendations (Illumina). Array
data export processing and analysis was performed using Illumina GenomeS-
tudio v.20092 (Gene Expression Module v.1.5.4). GSEA (https://www.
broadinstitute.org/gsea/) was used to analyze the enrichment of signaling
target genes that are upregulated by WNT and SHH.
REMBRANDT Data Analysis
The Repository of Molecular Brain Neoplasia Data (REMBRANDT) (Madhavan
et al., 2009) database was used to analyze correlations between clinical char-
acteristics, survival, and gene expression in glioma specimens. The study flow
is described in Figure S6. Patient groups were divided according to above and
below the mean of ID1 (probe 208937_s_at)/Cullin3 (probe 201372_s_at)
expression levels.
Statistical Analysis
Student’s t tests were used to analyze statistical significance in the paired
groups. One-way ANOVA was used to analyze statistical significance in multi-
ple groups (more than two groups). Overall survival of glioblastoma patients
was reported using Kaplan-Meier curves and significance was determined
by log-rank analysis. Cox proportional hazard modeling was used to perform
univariate and multivariate analyses. Data are expressed as means and 95%
confidence intervals (CIs). All statistical tests were two sided, and p < 0.05
was statistically significant.(C) Pie graph showing GBM subtype composition in patient groups divided acco
value, **p < 0.01.
(D) Kaplan-Meier survival curves of patient groups divided according to ID1 and
indicated high and low expression. Log rank **p < 0.01.
(E) Rank-ordered list of correlation coefficients (r values) between HH or WNT sig
database.
(F) GSC5-VEC and GSC5-ID1 cells were treated with siNT or siLRP5/6 for 1 day
WNT3a for 1 day, WNT signaling activity in these cells was examined by analyzin
(G) GSC5-VEC andGSC5-ID1 cells were treatedwith DMSOor cyclopamine for 1
SHH-N for 1 day, SHH signaling activity in these cells was examined by analyzin
(H and I) In vitro limiting dilution assays with different plating densities were used to
and GSC8 cells (I) treated with JW67 (Ink4a/Arf/ astrocytes-ID1; 4.1 mM, GSC8
combinatorial treatments (JW67+GANT61). **p < 0.01 (n = 24).Soft-Agar Assay, Plasmids and Gene Transduction, RT-PCR,
Immunofluorescence Assay and H&E Staining, FACS Analysis,
Subcutaneous Implantation Assay, Immunoprecipitation, Denature
Immunoprecipitation, and MALDI-TOF Assay
Detailed experimental procedures are provided in the Supplemental
Information.
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